Quest Diagnostics: Strong Q3, Steady (Not Spectacular) Growth Ahead

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, aimed at both novice and experienced investors [1] - The newsletter provides insights on key trends, catalysts driving valuations, product sales forecasts, and integrated financial statements for major pharmaceutical companies [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the investing group Haggerston BioHealth and has compiled detailed reports on more than 1,000 companies [1]